Outset Medical (NASDAQ:OM) (NASDAQ: OM) is a medical technology company focused on transforming the delivery of dialysis therapy around the world. Founded in 2011 and headquartered in San Jose, California, the company was established with the mission of making dialysis more accessible, efficient, and patient-centric. Outset’s flagship product, the Tablo® Hemodialysis System, was designed to simplify and accelerate the setup process, reduce the footprint of dialysis machines, and support both hospital-based and home-based treatments.
The Tablo System integrates dialysis water purification, machine intelligence, and cloud connectivity into a single platform. By automating setup, self-checking for treatment readiness, and offering on-machine user guidance, Tablo enables clinical staff and patients to perform hemodialysis with minimal training. The device’s compact design and integrated water system help lower staffing burdens and expand access to care in a variety of settings, from intensive care units to outpatient clinics and home environments.
Outset Medical has secured regulatory approvals for Tablo in major markets, including the United States, Canada, and the European Union, and continues to pursue additional clearances in regions across Asia Pacific and Latin America. The company’s commercial strategy emphasizes partnerships with healthcare providers, hospital systems, and dialysis networks to integrate Tablo into existing care pathways. By leveraging real-time data collection and analytics, Outset supports quality improvement initiatives and helps providers optimize treatment protocols to enhance patient outcomes.
Led by CEO Leslie Trigg and a seasoned executive team with deep experience in medical devices, healthcare operations, and technology innovation, Outset Medical invests heavily in research and development. The company maintains collaborations with clinical investigators, healthcare institutions, and patient advocacy groups to refine its technology, expand its product portfolio, and address unmet needs in kidney care. As the global burden of kidney disease continues to rise, Outset’s integrated approach seeks to improve the lives of millions of patients requiring renal replacement therapy.
